A key operating metric is the number of genes shipped, referring to the manufactured synthetic DNA, each ordered through a customizable online process.

The company shipped products to approximately 1,900 customers in Q3, versus 1,800 in the period last year, implying an expanding revenue per customer which provides some visibility to the forward outlook. The pace also accelerated during the quarter with sales up 17% over Q2. Revenue reached $56.1 million, up 60% year-over-year.

While higher spending and investments in support of growth explain the larger loss, the real story here is the strong operational momentum. Twist reported its fiscal Q3 results on August 5th with a net loss of $60.5 million or -$1.08 per share, compared to a loss of $40 million loss in the period last year. This article recaps recent developments including the latest quarterly report while we reaffirm our long-term bullish view for the stock. Indeed, the stock is off more than 50% from its 2021 high despite what has been overall strong operating momentum. While shares held onto a solid gain for much of 2021, the story since Q4 has been significant volatility amid the extreme market selloff, particularly in this segment of the high-growth, yet unprofitable tech companies. We last covered TWST with an article back in 2020, highlighting what was then a ' breakout year' for the company in terms of showcasing its market potential. The applications here for this type of ' engineered biology ' cover everything from the diagnosis and treatment of disease in healthcare, genetically modified agriculture, high-tech materials production, and even working as a form of large data set storage. Through software, the process is capable of driving thousands of chemical reactions to write strands of DNA significantly more effectively than alternative methods. ( NASDAQ: TWST) commercializes a DNA synthesis platform that automates synthetic DNA production on a silicon chip. In that settlement, neither Agilent nor Twist admitted any liability or wrongdoing.Twist Bioscience Corp. Agilent, a 20-year old synthetic DNA manufacturer, alleged that Leproust misappropriated trade secrets and was in breach of contract when she left Agilent to start Twist with co-founders Bill Banyai and Bill Peck. Smith had previously helped lead the expansion of a government affairs program at Gilead.Īnd in February, Twist and Leproust spent $22.5 million to settle one of the biggest issues hanging over the company - a four-year legal battle over Leproust’s departure from Agilent. In July, the company tapped Erin Smith to be its senior vice president of government affairs and public policy, a newly-created position.

Twist will create a TCR library - a self-proclaimed “library of libraries” - to aid Neogene’s search for engineered TCRs against targets in cancer, and Twist will also use the library to discover antibodies for future Neogene CAR-T candidates. Most recently, the company in October announced a collaboration with Neogene to study CAR-T and TCR therapies for cancer patients. However, Twist said it expected the plant to bring some 400 jobs to the area by the time it’s up and running.īeyond its “factory of the future,” Twist has had a busy 2020. The capital outlay associated with the facility, located more specifically in Wilsonville, was kept under wraps. “The (factory) allows us to support the increasing needs of our customers as they scale globally and plan for aggressive growth into synthetic biology and biopharma market segments we cannot serve today.” “We are expanding our customer base and ramping production of our products at an exceptional rate,” she said.

Twist bioscience